Analysts Expect Pfizer (PFE) to Deliver a Blowout Q3
Our preview of the upcoming week's earnings reports includes Pfizer (PFE), Square (SQ) and Moderna (MRNA).
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Delivered daily
Kiplinger Today
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more delivered daily. Smart money moves start here.
Sent five days a week
Kiplinger A Step Ahead
Get practical help to make better financial decisions in your everyday life, from spending to savings on top deals.
Delivered daily
Kiplinger Closing Bell
Get today's biggest financial and investing headlines delivered to your inbox every day the U.S. stock market is open.
Sent twice a week
Kiplinger Adviser Intel
Financial pros across the country share best practices and fresh tactics to preserve and grow your wealth.
Delivered weekly
Kiplinger Tax Tips
Trim your federal and state tax bills with practical tax-planning and tax-cutting strategies.
Sent twice a week
Kiplinger Retirement Tips
Your twice-a-week guide to planning and enjoying a financially secure and richly rewarding retirement
Sent bimonthly.
Kiplinger Adviser Angle
Insights for advisers, wealth managers and other financial professionals.
Sent twice a week
Kiplinger Investing Weekly
Your twice-a-week roundup of promising stocks, funds, companies and industries you should consider, ones you should avoid, and why.
Sent weekly for six weeks
Kiplinger Invest for Retirement
Your step-by-step six-part series on how to invest for retirement, from devising a successful strategy to exactly which investments to choose.
It has been a strong earnings season so far, with about 82% of the S&P 500 companies that have reported so far exceeding analysts' earnings estimates, according to FactSet.
This week promises another jam-packed earnings calendar, with blue-chip pharmaceutical firm Pfizer (PFE, $43.55) among those releasing results.
The Dow Jones stock had a strong start to the year, rallying from its Dec. 31 close at $36.81 to its Aug. 17 record high at $50.42. Helping fuel the shares were strong sales of the company's COVID-19 vaccine – developed alongside BioNTech (BNTX). This was evidenced in PFE's second-quarter results, with vaccine revenues surging 640% year-over-year (YoY) and total revenues up 92% from the year prior. PFE shares climbed more than 3% in response.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Investors are likely hoping for another positive reaction to Pfizer's third-quarter earnings report – slated on the earnings calendar for the morning of Nov. 2 – especially considering the stock is down about 14% from that aforementioned peak.
Analysts are certainly targeting solid growth for Pfizer's September quarter. On average, they're looking for revenues of $22.8 billion and earnings per share (EPS) of $1.09 – both huge improvements over last year's $12.7 billion in sales and 72 cents per share in profits.
"Pfizer is on track to generate strong revenue and operating cash flow in 2021, with a large contribution from its COVID-19 vaccine," says Argus Research analyst David Toung, who has a Buy rating on the stock. "Since the 2Q 2021 earnings report, the company has signed additional contracts for the vaccine, which has also received Food and Drug Administration (FDA) authorization as a booster shot."
And beyond the COVID-19 vaccine, the analyst likes PFE's solid pipeline of biologics, strong research and development (R&D) capabilities, and "innovative" biopharma business, which includes "growth drivers" such as chemotherapy drug Ibrance, blood thinner Eliquis and pneumococcal conjugate vaccine Prevnar 13 among others.
However, Mizuho Securities analysts believe consensus estimates for Pfizer's third quarter are "likely too high." Specifically, they point to prescription trends from healthcare data analysis firm IQVIA and what they believe are likely lower-than-anticipated COVID-19 vaccine sales based on "orders that Pfizer has publicly announced and government websites that track actual COVID vaccine shipments."
Looking past Q3, the analysts – who have a Neutral (Hold) rating on PFE – "expect significant attention on the conference call on how management sees COVID-19 vaccine sales evolving over the next several quarters and management expectations on Pfizer's oral protease inhibitor targeting COVID-19 ahead of top-line data later this quarter."
The team will also be looking for commentary on "other mid-late stage pipeline assets, as well as Pfizer's business development priorities, as the company works to improve its 2026-2030 outlook."
Analyst: Square Q3 Will Be Soft, But Tailwinds Are Ahead
Square (SQ, $256.20), like so many other stocks, had a volatile, yet positive month of October. The shares rallied about 10% off their early month lows near $233, widening their year-to-date lead to nearly 18%.
The payments processor turned in blowout results in its second quarter – reporting triple-digit percentage growth on both the top and bottom lines from the year prior – but Jefferies analyst Trevor Williams doesn't think a repeat is in store.
"We expect fewer surprises than in the second quarter as investors brace for soft results after macro-turbulence in August, a deceleration in e-commerce and easing forex tailwinds," he writes in a note.
Longer term, though, he sees a "favorable setup" into 2022, with Square's acquisition of Australian buy-now, pay-later firm Afterpay expected to close in the first quarter and several new Cash App initiatives. He has a Buy rating on the fintech stock and says bulls "expect any near-term weakness to be short-lived."
Square will report its third-quarter earnings after the Nov. 4 close. Analysts, on average, are expecting $4.5 billion in revenues (+49.6% YoY) and earnings of 39 cents per share, a 14.7% improvement of its year-ago results.
Moderna Earnings Estimates High, But Sentiment Low
Moderna (MRNA, $342.87) is another healthcare stock that hit a record high in August but has since pulled back. The shares are down about 30% from that mid-August peak.
However, even with this pullback, Deutsche Bank analyst Emmanuel Papadakis thinks the shares are still extremely overvalued and has a Sell rating and $250 price target on the stock. As we detailed recently in our free A Step Ahead e-letter, Papadakis sees the COVID-19 vaccine maker's business as being fundamentally sound, but its valuation "looks detached from a problematic assessment of reality."
Needham analyst Joseph Stringer isn't exactly upbeat toward Moderna, either. He has a Hold rating on the shares, "based on our belief that success in COVID vaccine programs is fully reflected in the stock."
As for Moderna's Thursday morning third-quarter earnings report: the pros, on average, are looking for EPS of $9.09 compared to a per share loss of 59 cents in the year-ago period. As for revenues, they're targeting $6.2 billion – a more than 7,944% YoY improvement.
-
Ask the Tax Editor: Federal Income Tax DeductionsAsk the Editor In this week's Ask the Editor Q&A, Joy Taylor answers questions on federal income tax deductions
-
States With No-Fault Car Insurance Laws (and How No-Fault Car Insurance Works)A breakdown of the confusing rules around no-fault car insurance in every state where it exists.
-
7 Frugal Habits to Keep Even When You're RichSome frugal habits are worth it, no matter what tax bracket you're in.
-
If You'd Put $1,000 Into AMD Stock 20 Years Ago, Here's What You'd Have TodayAdvanced Micro Devices stock is soaring thanks to AI, but as a buy-and-hold bet, it's been a market laggard.
-
If You'd Put $1,000 Into UPS Stock 20 Years Ago, Here's What You'd Have TodayUnited Parcel Service stock has been a massive long-term laggard.
-
If You'd Put $1,000 Into Lowe's Stock 20 Years Ago, Here's What You'd Have TodayLowe's stock has delivered disappointing returns recently, but it's been a great holding for truly patient investors.
-
If You'd Put $1,000 Into 3M Stock 20 Years Ago, Here's What You'd Have TodayMMM stock has been a pit of despair for truly long-term shareholders.
-
Nasdaq Leads as Tech Stages Late-Week Comeback: Stock Market TodayOracle stock boosted the tech sector on Friday after the company became co-owner of TikTok's U.S. operations.
-
Stocks Chop as the Unemployment Rate Jumps: Stock Market TodayNovember job growth was stronger than expected, but sharp losses in October and a rising unemployment rate are worrying market participants.
-
If You'd Put $1,000 Into Coca-Cola Stock 20 Years Ago, Here's What You'd Have TodayEven with its reliable dividend growth and generous stock buybacks, Coca-Cola has underperformed the broad market in the long term.
-
If You Put $1,000 into Qualcomm Stock 20 Years Ago, Here's What You Would Have TodayQualcomm stock has been a big disappointment for truly long-term investors.
